Marlon Silva

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 783 citations · Full text

Medicine, Oncology, Urology +17

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

Paul Sargos, Sylvie Chabaud, I. Latorzeff et al. · The Lancet Oncology · 2020 · 322 citations · Full text

Medicine, Oncology, Urology +17

OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer

S. Supiot, Loïg Vaugier, Xavier Buthaud et al. · European Urology · 2021 · 91 citations · Full text

Medicine, Oncology, Urology +13

Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG

Geoffrey Martinage, G. Janoray, Damaris Patricia Rojas et al. · International Journal of Radiation Oncology*Biology*Physics · 2019 · 76 citations · Full text

Medicine, Radiation Oncology, Urology +13

Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

Alberto Bossi, Stéphanie Foulon, Xavier Maldonado et al. · Journal of Clinical Oncology · 2023 · 56 citations

Medicine, Oncology, Radiation Oncology +17